相关实验视频
Updated: Sep 14, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
纤维酸在与代谢功能障碍相关的脂肪性肝病中:系统性审查和元分析
Manoj Kumar1, Avivar Awasthi2, Deep Dutta3
1Department of Endocrinology, Maharishi Markandeshwar Institute of Medical Sciences, Ambala, Haryana, India.
费诺纤维酸是一种与代谢功能障碍相关的脂肪性肝病 (MASLD) 的安全治疗方法,对肝酶和脂肪含量表现出中性作用. 它有效降低MASLD患者的甘油三.
科学领域:
- 肝病学和代谢障碍 肝病和代谢障碍
- 对于肝脏疾病的药理干预措施
背景情况:
- 费诺纤维酸是治疗高甘油三血症的标准治疗方法.
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 经常与高甘油三血症共存.
- 纤维酸对MASLD的影响尚未被系统地审查.
研究的目的:
- 对MASLD患者的费诺纤维酸的作用进行系统性审查和元分析 (SRM).
- 为了评估纤维酸对肝酶,肝脂肪,脂质参数和MASLD中的安全性的影响.
主要方法:
- 在电子数据库中搜索随机对照试验 (RCT),比较MASLD患者的费诺纤维酸与安慰剂或活性对照.
- 主要结局包括氨基转移酶 (ALT) 和酸氨基转移酶 (AST) 的变化.
- 二次结局评估了肝脏脂肪含量,脂质概况和不良事件.
主要成果:
- 对5项RCT的分析发现,与活性对照剂 (atorvastatin,omega-3脂肪酸,pioglitazone) 相比,费诺纤维酸对ALT和AST具有可比的影响.
- 与活性对照剂相比,费诺纤维酸在甘油三中显著降低.
- 费诺纤维酸使用与肝脏脂肪的非显著增加有关,这可能是由于比较药物 (皮奥格利塔,O3FA) 的减脂作用.
结论:
- 费诺纤维酸在MASLD患者中显示出令人放心的安全性.
- 对于MASLD.中的肝脂肪含量,纤维酸在很大程度上是中立的.
- 费诺纤维酸保持其有效性,显著降低MASLD中的甘油三水平.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
07:12Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
Published on: June 2, 2023
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Hepatic Drug Excretion: Influencing Factors
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...